Impact News +++ Teleflex to sell acute care, interventional urology, OEM units for $2.03B (SeekingAlpha) +++ TELEFLEX Aktie +6,83%

IPSEN Aktie

>IPSEN Aktienkurs

123.5 EUR (Tradegate)

Ask: 123.6 EUR / 40 Stück

Bid: 123.4 EUR / 40 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IPSEN Aktie über LYNX handeln

Intraday

1 Jahr

>IPSEN Performance

1 Woche: -0,5%

1 Monat: -0,6%

3 Monate: +4,4%

6 Monate: +18,4%

1 Jahr: +12,8%

laufendes Jahr: +11,8%

>IPSEN Aktie

Name:

IPSEN S.A. PORT. EO 1

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0010259150 / A0ESMG

Symbol/ Ticker:

I7G (Frankfurt)

Kürzel:

FRA:I7G, ETR:I7G, I7G:GR

Index:

Webseite:

https://www.ipsen.com/

Profil:

Ipsen S.A. is a global biopharmaceutical company s..
>Volltext..

Marktkapitalisierung:

10072.61 Mio. EUR

Unternehmenswert:

9591.25 Mio. EUR

Umsatz:

3601.12 Mio. EUR

EBITDA:

1611.91 Mio. EUR

Nettogewinn:

452.93 Mio. EUR

Gewinn je Aktie:

5.48 EUR

Schulden:

972.61 Mio. EUR

Liquide Mittel:

1461.24 Mio. EUR

Operativer Cashflow:

983.93 Mio. EUR

Bargeldquote:

1.02

Umsatzwachstum:

9.57%

Gewinnwachstum:

-34.25%

Dividende je Aktie:

1.4 EUR

Dividendenrendite:

1.15%

Dividendenschätzung:

1.14%

Div. Historie:

04.06.25 - 1.4€
30.05.24 - 1.2€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

IPSEN

Letzte Datenerhebung:

09.12.25

>IPSEN Kennzahlen

Aktien/ Unternehmen:

Aktien: 82.71 Mio. St.

Frei handelbar: 41.78%

Leerverk. Aktien: -

Rückkaufquote: 0.34%

Mitarbeiter: 5358

Umsatz/Mitarb.: 0.56 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: 4.9%

Bewertung:

KGV: 23.1

KGV lG: 10.66

KUV: 2.94

KBV: 2.43

PEG-Ratio: -

EV/EBITDA: 5.95

Rentabilität:

Bruttomarge: 82.39%

Gewinnmarge: 12.58%

Operative Marge: 33.67%

Managementeffizenz:

Gesamtkaprendite: 6.7%

Eigenkaprendite: 10.82%

>IPSEN Peer Group

Es sind 69 Aktien bekannt.

>IPSEN Chart & Kurs - Tradegate

>IPSEN News

08.12.25 - 18:33	Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
	Monthly information relative to the total number of voting rights and shares composing the share capital...

05.12.25 - 07:00

Ipsen provides update on legacy of Henri Beaufour (GlobeNewswire EN)

PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen's Board Member and a representative of the founding family who passed away on November 28, 2025. This transfer is expected to take place in early 2026 after having obtained the required regulatory approvals*....

02.12.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025 (GlobeNewswire EN)
	Attachment...

01.12.25 - 07:03	Ipsen mourns the passing of Henri Beaufour, a founding family Board member (GlobeNewswire EN)
	PARIS, FRANCE, 1 DECEMBER 2025 - It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025....

27.11.25 - 23:33	Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline \| DelveInsight (PR Newswire)
	The rhabdomyosarcoma market is expanding as unmet needs in pediatric and young-adult populations drive increased R&D and clinical activity. Additionally, the launch of emerging therapies such as Cabozantinib (Exelixis/Ipsen), PEEL-224 (Peel Therapeutics), Orotecan (Edison Oncology),......

25.11.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 47 - 2025 (GlobeNewswire EN)
	...

19.11.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 46 - 2025 (GlobeNewswire EN)
	Attachment...

12.11.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025 (GlobeNewswire EN)
	Attachment...

07.11.25 - 18:03	Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
	Monthly information relative to the total number of voting rights and shares composing the share capital...

07.11.25 - 14:45	Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®′s long-term efficacy, safety and mechanistic insights in fatigue (GlobeNewswire EN)
	Paris, France – 7 November, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new Primary Biliary Cholangitis (PBC) data with IQIRVO® from the ELATIVE trial1, 2 will be presented in two late-breaking sessions, at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD). ...

06.11.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2025 (GlobeNewswire EN)
	Attachment...

28.10.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2025 (GlobeNewswire EN)
	Attachment...

22.10.25 - 14:24	Ipsen übertrifft Prognosen und hebt Jahresziel an – Aktie legt deutlich zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

22.10.25 - 11:31	Ipsen Q3 Total Sales Rise, Lifts FY25 Outlook; To Buy ImCheck; Stock Up (AFX)
	PARIS (dpa-AFX) - Ipsen S.A. (IPSEY, IPN.PA), a specialty-care biopharmaceutical company, Wednesday reported higher total sales for the third quarter compared to last year, mainly driven by strong......

22.10.25 - 11:01	Ipsen stock jumps 6% after upbeat Q3 and higher outlook on Somatuline boost (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

22.10.25 - 10:03	EQT Life Sciences′ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion (PR Newswire)
	Ipsen and ImCheck Therapeutics have entered into a definitive share purchase agreement. ImCheck's shareholders will be eligible to receive a payment of EUR 350 million and downstream payments, for a total potential consideration of up to EUR 1 billion. ImCheck Therapeutics is a private......

22.10.25 - 09:48	Ipsen To Buy ImCheck Therapeutics In Up To $1 Bln Deal; Stock Up (AFX)
	PARIS (dpa-AFX) - Ipsen S.A. (IPSEY, IPN.PA), a biopharmaceutical company, Wednesday announced that it entered into a definite agreement to purchase ImCheck Therapeutics for a total consideration ......

22.10.25 - 09:15	Ipsen S.A. reports Q3 results; upgrades FY outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.10.25 - 09:03	Corporate News: Andera Partners (EQS)
	Ipsen to acquire ImCheck Therapeutics, in Andera Partners' portfolio, expanding its leadership in oncology, strengthening its pipeline...

22.10.25 - 07:09	Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance (GlobeNewswire EN)
	PARIS, FRANCE, 22 October 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ist das Maisfeld fern vom Haus, fressen die Vögel die Frucht. - Sprichwort Pygmäen

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram